JP2024512741A5 - - Google Patents

Info

Publication number
JP2024512741A5
JP2024512741A5 JP2023560694A JP2023560694A JP2024512741A5 JP 2024512741 A5 JP2024512741 A5 JP 2024512741A5 JP 2023560694 A JP2023560694 A JP 2023560694A JP 2023560694 A JP2023560694 A JP 2023560694A JP 2024512741 A5 JP2024512741 A5 JP 2024512741A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
sequence shown
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560694A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512741A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2022/050442 external-priority patent/WO2022204793A1/en
Publication of JP2024512741A publication Critical patent/JP2024512741A/ja
Publication of JP2024512741A5 publication Critical patent/JP2024512741A5/ja
Pending legal-status Critical Current

Links

JP2023560694A 2021-03-31 2022-03-25 腫瘍及び/又は免疫細胞を標的化する結合剤 Pending JP2024512741A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163168606P 2021-03-31 2021-03-31
US63/168,606 2021-03-31
US202163249784P 2021-09-29 2021-09-29
US63/249,784 2021-09-29
US202263301305P 2022-01-20 2022-01-20
US63/301,305 2022-01-20
PCT/CA2022/050442 WO2022204793A1 (en) 2021-03-31 2022-03-25 Binding agents targeting tumors and/or immune cells

Publications (2)

Publication Number Publication Date
JP2024512741A JP2024512741A (ja) 2024-03-19
JP2024512741A5 true JP2024512741A5 (cg-RX-API-DMAC7.html) 2025-04-03

Family

ID=83455216

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560694A Pending JP2024512741A (ja) 2021-03-31 2022-03-25 腫瘍及び/又は免疫細胞を標的化する結合剤

Country Status (7)

Country Link
US (1) US20240166739A1 (cg-RX-API-DMAC7.html)
EP (1) EP4314076A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024512741A (cg-RX-API-DMAC7.html)
AR (1) AR125264A1 (cg-RX-API-DMAC7.html)
CA (1) CA3174330A1 (cg-RX-API-DMAC7.html)
TW (1) TW202304993A (cg-RX-API-DMAC7.html)
WO (1) WO2022204793A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4599066A1 (en) * 2022-10-03 2025-08-13 Kisoji Biotechnology Inc. Multispecific binding agents targeting dopamine receptor d2 and methods of use thereof
CN120265659A (zh) * 2022-10-25 2025-07-04 加拿大商木曾路生物科技公司 靶向表达cd36的肿瘤细胞的结合剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009508521A (ja) * 2005-09-23 2009-03-05 アカデミッシュ ジーケンハイス レイデン タンパク凝集に関連する疾患の診断予防及び治療のためのvhh
CA2747644C (en) * 2008-12-19 2023-01-24 Ablynx N.V. Method for generation of immunoglobulin sequences
WO2011051327A2 (en) * 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
US20180222966A1 (en) * 2013-04-29 2018-08-09 Agrosavfe N.V. Transgenic plant comprising a polynucleotide encoding a variable domain of heavy-chain antibody
US10874685B2 (en) * 2014-04-17 2020-12-29 The Royal Institution For The Advancement Of Learning/Mcgill University Pancreatic cancer therapy and diagnosis
CA2975655C (en) * 2015-02-05 2023-09-19 Janssen Vaccines & Prevention B.V. Binding molecules directed against influenza hemagglutinin and uses thereof
CA3065999A1 (en) * 2017-05-24 2018-11-29 Nanosomix, Inc. Detection of biomarkers on vesicles for the diagnosis and prognosis of diseases and disorders
WO2019179434A1 (en) * 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/cd47 antibody molecules
CN114072426B (zh) * 2019-07-08 2024-01-26 南京金斯瑞生物科技有限公司 抗cd47/抗pd-1双特异抗体及其制备方法和应用

Similar Documents

Publication Publication Date Title
JP7140861B2 (ja) ヘテロ二量体多重特異性抗体フォーマット
JP2020505919A5 (cg-RX-API-DMAC7.html)
JP2021098732A5 (cg-RX-API-DMAC7.html)
JP2024532485A5 (cg-RX-API-DMAC7.html)
JP2021524268A5 (cg-RX-API-DMAC7.html)
JP2021525546A5 (cg-RX-API-DMAC7.html)
JP7549961B2 (ja) 少なくともcd3及びhsaを標的とするヘテロ二量体多重特異性抗体フォーマット
JP2021159081A5 (cg-RX-API-DMAC7.html)
FI2155783T4 (fi) Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni
JP2014158485A5 (cg-RX-API-DMAC7.html)
JP2023507033A5 (cg-RX-API-DMAC7.html)
JP2025160226A5 (cg-RX-API-DMAC7.html)
JP2021520832A5 (cg-RX-API-DMAC7.html)
JP2023516004A5 (cg-RX-API-DMAC7.html)
CN114901696A (zh) 人源化cldn18.2抗体
CN110869390A (zh) 抗pd-l1抗体及其用途
JP2022532370A5 (cg-RX-API-DMAC7.html)
CN111378044A (zh) 抗体融合蛋白、制备方法及其应用
CN115605513A (zh) 一种抗pd-l1和her2的双特异性抗体
JP2024543822A5 (cg-RX-API-DMAC7.html)
JP2021529524A5 (cg-RX-API-DMAC7.html)
JP2015520172A5 (cg-RX-API-DMAC7.html)
US12312418B2 (en) Orthogonal mutations for heterodimerization
CA3162773A1 (en) Tumor-specific claudin 18.2 antibodies
Power et al. Construction, expression and characterisation of a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a heat-inducible bacterial secretion vector